GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » cbdMD Inc (AMEX:YCBD) » Definitions » GF Score

cbdMD (YCBD) GF Score : 42/100 (As of Apr. 01, 2025)


View and export this data going back to 2017. Start your Free Trial

What is cbdMD GF Score?

cbdMD has the GF Score of 42, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 4/10
2. Profitability Rank : 2/10
3. Growth Rank : 3/10
4. GF Value Rank : 0/10
5. Momentum Rank : 5/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes cbdMD might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Competitive Comparison of cbdMD's GF Score

For the Drug Manufacturers - Specialty & Generic subindustry, cbdMD's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


cbdMD's GF Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, cbdMD's GF Score distribution charts can be found below:

* The bar in red indicates where cbdMD's GF Score falls into.


;
;

cbdMD  (AMEX:YCBD) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.


cbdMD GF Score Related Terms

Thank you for viewing the detailed overview of cbdMD's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.


cbdMD Business Description

Traded in Other Exchanges
Address
2101 Westinghouse Boulevard, Suite A, Charlotte, NC, USA, 28273
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
Executives
Thomas Ronan Kennedy officer: Interim CEO and CFO 8845 RED OAK BLVD, CHARLOTTE NC 28217
Bakari T. Sellers director 4231 VOORHEES ROAD, DENMARK SC 29042
Raines William F Iii director 8314 TOSOMOCK LANE, HUNTERSVILLE NC 28078
Scott G. Stephen director 4249 NORTH WINCHESTER AVE., CHICAGO IL 60613
Sibyl Nichole Swift director 730 HAWTHORNE LANE, APT 441, CHARLOTTE NC 28204
Kevin Macdermott officer: President 9580 CALDWELL RD, MOUNT ULLA NC 28125
Wiesehan John J Iii officer: Chief Revenue Officer 8845 RED OAK BOULEVARD, CHARLOTTE NC 28217
Sim Farar director 8845 RED OAK BOULEVARD, CHARLOTTE NC 28217
Martin A. Sumichrast director, officer: Chairman of the Board and CEO 11125 COLONIAL COUNTRY LANE, CHARLOTTE NC 28277
Raymond Scott Coffman director 230 S. TRYON ST., #1302, CHARLOTTE NC 28202
Peter J. Ghiloni director 115 DEER ESTATES LANE, PONTE VEDRA BEACH FL 32082
Mark S Elliott officer: CFO & COO C/O LEVEL BRANDS, INC., 4521 SHARON ROAD, SUITE 450, CHARLOTTE NC 28211
Gregory C Morris director 421 CRANBORNE CHASE, FORT MILL SC 29708
Caryn Nicole Dunayer officer: President 8476 CATAWBA DOVE DR., BELMONT NC 28012
Erik Sterling 10 percent owner 5505 KALANIANAOLE HWY, HONOLULU HI 96821

cbdMD Headlines

From GuruFocus

Q2 2024 cbdMD Inc Earnings Call Transcript

By GuruFocus Research 05-16-2024

Q4 2024 cbdMD Inc Earnings Call Transcript

By GuruFocus News 12-27-2024

Q2 2020 cbdMD Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q1 2024 cbdMD Inc Earnings Call Transcript

By GuruFocus Research 02-14-2024

cbdMD Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 02-15-2024

Q3 2020 cbdMD Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q1 2021 cbdMD Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q3 2022 cbdMD Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q2 2023 cbdMD Inc Earnings Call Transcript

By GuruFocus Research 02-15-2024

Q3 2024 cbdMD Inc Earnings Call Transcript

By GuruFocus Research 08-16-2024